期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 70, 期 -, 页码 13-25出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2023.03.001
关键词
SARS-CoV-2; Omicron; Immune evasion; Mutations; Booster; Bivalent mRNA vaccine
Since its emergence in 2019, SARS-CoV-2 has infected over 600 million people worldwide, causing significant damage to global medical, economic, and political structures. The highly mutated Omicron variant has evolved into multiple subvariants, with mutations in the spike protein affecting its antigenic structure and affinity for ACE2. These mutations allow Omicron to evade immunity from natural infection and vaccination. This review assesses the immune evasion capacity of SARS-CoV-2, focusing on neutralizing antibodies generated by different vaccination regimes, to improve our ability to combat emerging Omicron variants.
Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has significant damage to global medical, economic, and political structures. Currently, a highly mutated variant of concern, SARS-CoV-2 Omicron, has evolved into many different subvariants mainly including BA.1, BA.2, BA.3, BA.4/5, and the recently emerging BA.2.75.2, BA.2.76, BA.4.6, BA.4.7, BA.5.9, BF.7, BQ.1, BQ.1.1, XBB, XBB.1, etc. Mutations in the N-terminal domain (NTD) of the spike protein, such as A67V, G142D, and N212I, alter the antigenic structure of Omicron, while mutations in the spike receptor binding domain (RBD), such as R346K, Q493R, and N501Y, increase the affinity for angiotensin-converting enzyme 2 (ACE2). Both types of mutations greatly increase the capacity of Omicron to evade immunity from neutralizing antibodies, produced by natural infection and/or vaccination. In this review, we systematically assess the immune evasion capacity of SARS-CoV-2, with an emphasis on the neutralizing antibodies generated by different vaccination regimes. Understanding the host antibody response and the evasion strategies employed by SARS-CoV-2 variants will improve our capacity to combat newly emerging Omicron variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据